Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
This study has been completed.
Study NCT00192166
Information provided by MedImmune LLC
First Received on September 12, 2005.
Last Updated on December 5, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study: